Myeloid & Lymphoid disorders in practice - 2010


Comment: Whole genome sequencing – a routine diagnostic test?
John Reilly
pp 2-2
Sequencing of the entire human genome was first announced on 26 June 2000. This feat was one that took ten years and cost an estimated $3.5 billion of taxpayers’ money. At the time, a number of eminent scientists voiced concern that the project should not be given priority funding, since the resultant knowledge was unlikely to produce significant clinical rewards. With the benefit of hindsight, was this scepticism justified?
Defining the role of late effects monitoring in AML
Diana Greenfield, Richard Ross and John Snowden
pp 3-8
In the last three decades, long-term survival in acute myeloid leukaemia (AML) has improved considerably. Despite the introduction of anthracycline- and cytarabine-based remission induction regimens, Medical Research Council trials from the 1970s show that the chances of long-term survival amounted to somewhere between 3% and 11%.
Familial myeloproliferative neoplasms
Archana M Agarwal and Josef T Prchal
pp 6-7
Chronic myeloproliferative neoplasms (MPNs) include polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Although these disorders usually occur sporadically, familial clustering of MPNs is also a well-established entity.
Atypical CML: a real diagnosis or one of exclusion?
Lian Wea Chia, Fernando Pinto and Timothy Chevassut
pp 9-11
Atypical chronic myeloid leukaemia (aCML) is currently regarded as a distinct histological and clinical entity that resides within the category of mixed myelodysplastic/myeloproliferative disorders. The defining feature that distinguishes aCML from classical CML is the absence of the BCR-ABL1 gene rearrangement; aCML is sometimes referred to as Philadelphia-negative (Ph-) CML. Considered to be a clonal stem cell disorder, it shares key features with other related myeloid diseases.
The use of erythropoiesis-stimulating agents in MDS
Paul Greaves, James Aries and Samir Agrawal
pp 12-16
Myelodysplastic syndrome (MDS) is a disorder of haematological progenitor cells leading to progressive bone marrow failure and, in some cases, acute leukaemia. Criteria for MDS have been outlined by the French–American–British (FAB) system and the World Health Organization (WHO).

refunds & cancellation | company profile | contact us | © 2010 - 2024